Job Opening at ADARx Pharmaceuticals Inc. for Sr. Clinical Trial Assistant.
ADARx Pharmaceuticals Inc.
Biotechnology Research
San Diego, CA 14,563 followers
Our vision is to provide effective and safe RNA therapeutics to patients who suffer from intractable diseases.
About us
ADARx Pharmaceuticals, Inc., located in San Diego, is a clinical stage biotechnology company committed to turning cutting-edge science into life-saving therapeutics. ADARx has developed proprietary RNA targeting platforms and oligonucleotide delivery technologies for inhibition, degradation, and editing disease-causing mRNA. ADARx has a growing pipeline of RNA targeting therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiometabolic, complement-mediated diseases and central nervous system diseases. We are well-financed by a syndicate of renowned VC firms. ADARx currently has multiple active programs in development. Our lead candidate is at the clinical stage.
- Website
-
http://adarx.com
External link for ADARx Pharmaceuticals Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- San Diego, CA
- Type
- Privately Held
- Founded
- 2019
Locations
-
Primary
Get directions
5871 Oberlin Drive
San Diego, CA 92121, US
Employees at ADARx Pharmaceuticals Inc.
Updates
-
We look forward to supporting the angioedema community in Madrid tomorrow at the 2026 HAE International (HAEi) Global Angioedema Leadership Conference, where Dr. Marc Riedl will share a poster highlighting new clinical data on Onvuzosiran (ADX-324), our #siRNA-based therapeutic candidate targeting plasma kallikrein. #26GALC #HAEi #ACARE #Angioedema
-
We’re happy to share that we have expanded our leadership team with the appointment of Ryan Fisk as Chief Financial Officer and Chief Business Officer. With more than two decades of experience advising innovative biotech companies on strategic and financial transactions, his expertise in aligning capital strategy with key clinical and corporate milestones will be instrumental as we advance our #siRNA therapeutic pipeline and expand strategic growth opportunities. Welcome to the team, Ryan! Learn more here: https://lnkd.in/ey6evK2r
-
-
We’re excited to share we presented Phase 1/2 data for onvuzosiran (ADX-324), a novel #siRNA therapeutic candidate being evaluated in a Phase 3 clinical trial for the treatment of #HAE, at the 2026 American Academy of Allergy, Asthma & Immunology - AAAAI Annual Meeting, demonstrating deep and durable reductions of plasma kallikrein levels with a favorable safety profile. These data support the potential of twice-yearly dosing with sustained attack-free rates, aiming to reduce the treatment burden for people living with HAE. Learn more here: https://lnkd.in/efGEusGB #AAAAI2026
-
We’re presenting clinical data from our onvuzosiran (ADX-324) program at the American Academy of Allergy, Asthma & Immunology - AAAAI 2026 Annual Meeting on Friday, February 27, 2026. Onvuzosiran is an investigational #siRNA therapeutic candidate being evaluated in a Phase 3 clinical trial for the treatment of #HAE. Learn more here: https://lnkd.in/erU7G4cj
-